JP7855515B2 - B型肝炎およびd型肝炎を治療および予防するための組成物および方法 - Google Patents

B型肝炎およびd型肝炎を治療および予防するための組成物および方法

Info

Publication number
JP7855515B2
JP7855515B2 JP2022546448A JP2022546448A JP7855515B2 JP 7855515 B2 JP7855515 B2 JP 7855515B2 JP 2022546448 A JP2022546448 A JP 2022546448A JP 2022546448 A JP2022546448 A JP 2022546448A JP 7855515 B2 JP7855515 B2 JP 7855515B2
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
seq
combination product
pres1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022546448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512526A (ja
JP2023512526A5 (cg-RX-API-DMAC7.html
Inventor
セルベルグ,マッティ
フレリン,ラーシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Svenska Vaccinfabriken Produktion AB
Original Assignee
Svenska Vaccinfabriken Produktion AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Svenska Vaccinfabriken Produktion AB filed Critical Svenska Vaccinfabriken Produktion AB
Publication of JP2023512526A publication Critical patent/JP2023512526A/ja
Publication of JP2023512526A5 publication Critical patent/JP2023512526A5/ja
Application granted granted Critical
Publication of JP7855515B2 publication Critical patent/JP7855515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
JP2022546448A 2020-01-28 2021-01-26 B型肝炎およびd型肝炎を治療および予防するための組成物および方法 Active JP7855515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966970P 2020-01-28 2020-01-28
US62/966,970 2020-01-28
PCT/US2021/015126 WO2021154752A1 (en) 2020-01-28 2021-01-26 Compositions and methods for treating and preventing hepatitis b and d

Publications (3)

Publication Number Publication Date
JP2023512526A JP2023512526A (ja) 2023-03-27
JP2023512526A5 JP2023512526A5 (cg-RX-API-DMAC7.html) 2024-01-18
JP7855515B2 true JP7855515B2 (ja) 2026-05-08

Family

ID=74673345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546448A Active JP7855515B2 (ja) 2020-01-28 2021-01-26 B型肝炎およびd型肝炎を治療および予防するための組成物および方法

Country Status (9)

Country Link
US (1) US20230079898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096711A1 (cg-RX-API-DMAC7.html)
JP (1) JP7855515B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220149519A (cg-RX-API-DMAC7.html)
CN (1) CN115335075A (cg-RX-API-DMAC7.html)
AU (1) AU2021214939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169407A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009169A (cg-RX-API-DMAC7.html)
WO (1) WO2021154752A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132332A1 (en) 2016-01-28 2017-08-03 Svenska Vaccinfabriken Produktion Ab Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101564533B (zh) * 2009-06-12 2012-01-04 东南大学 戊型肝炎蛋白-核酸复合疫苗及其制备方法
CN102895659B (zh) * 2011-07-29 2014-10-29 复旦大学 一种防治老年痴呆症复合疫苗及其制备方法
AU2017332854B2 (en) * 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132332A1 (en) 2016-01-28 2017-08-03 Svenska Vaccinfabriken Produktion Ab Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes

Also Published As

Publication number Publication date
AU2021214939A1 (en) 2022-09-15
KR20220149519A (ko) 2022-11-08
CN115335075A (zh) 2022-11-11
JP2023512526A (ja) 2023-03-27
CA3169407A1 (en) 2021-08-05
EP4096711A1 (en) 2022-12-07
US20230079898A1 (en) 2023-03-16
WO2021154752A1 (en) 2021-08-05
MX2022009169A (es) 2022-12-08

Similar Documents

Publication Publication Date Title
US11478544B2 (en) Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes
US8445663B2 (en) Compositions and methods that enhance an immune response
Le Guerhier et al. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model
WO2023225598A2 (en) Compositions and methods for treating hepatitis b virus (hbv) infection and hbv-associated diseases
JP2022536945A (ja) B型肝炎ウイルス(HBV)ワクチンおよびHBVを標的化するRNAiの組合せ
JP2023520370A (ja) コロナウイルスの治療および予防のための組成物および方法
EP4600272A1 (en) Treatment of chronic hepatitis b based on interferon synergistic immune checkpoint blocking antibody
WO2025261301A1 (zh) 一种抗原抗体复合物及其制备方法和应用
RU2812764C1 (ru) Композиции и способы для лечения и предотвращения гепатита в и d
US20250197452A1 (en) Compositions and methods for treating and preventing hepatitis b and d
US20230079898A1 (en) Compositions and methods for treating and preventing hepatitis b and d
HK40083708A (en) Compositions and methods for treating and preventing hepatitis b and d
RU2856944C1 (ru) Вакцинная композиция для индукции гуморального и клеточного ответа против вируса гепатита С
WO2025260241A1 (zh) 一种用于增强乙肝患者免疫应答的抗原抗体复合物疫苗及制备方法
Russell et al. PreS1-decorated recombinant adenovirus encoding HBV antigens generates neutralizing humoral and cellular immunity
TW202330575A (zh) 用於治療及預防冠狀病毒之組成物及方法
WO2024186780A2 (en) Compositions and methods for treating and preventing crimean congo hemorrhagic fever virus
Yoshida et al. HBs Antigen Reduction and Anti-HBs Induction Through the Nasal Administration of a Therapeutic Vaccine Containing HBs and HBc Antigen in Patients with Chronic Hepatitis B Virus Infection
AU2004281098A1 (en) Pharmaceutical compositions for therapeutic use
WO2021226343A1 (en) Dna antibody constructs for use against hepatitis b virus
HK40079522A (en) Chimeric antigens for treating viral infection
US20140286985A1 (en) Simple vaccines from dna launched suicidal flaviviruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240110

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260422

R150 Certificate of patent or registration of utility model

Ref document number: 7855515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150